Pharmacokinetics and Pharmacodynamics of Amoxicillin-Sulbactam, a Novel Aminopenicillin–β-Lactamase Inhibitor Combination, against Escherichia coli
- 1 June 1999
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 43 (6) , 1503-1504
- https://doi.org/10.1128/aac.43.6.1503
Abstract
We evaluated the pharmacokinetics of amoxicillin-sulbactam (AMX-SUL), a novel drug combination, and its pharmacodynamics against Escherichia coli in 12 volunteers receiving a single oral dose (1,000 mg). Peak serum bactericidal and urine inhibitory activities in most volunteers were observed against E. coli strains for which AMX-SUL MICs were low (2- to 4-mg/liter) (2 strains) and high (≥16-mg/liter) (47 strains), respectively.Keywords
This publication has 6 references indexed in Scilit:
- Construction by polymerase chain reaction and intragenic DNA probes for three main types of transferable β-lactamases (TEM, SHV, CARB)FEMS Microbiology Letters, 1991
- Sulbactam/AmpicillinDrugs, 1987
- Sulbactam/Ampicillin: In Vitro Spectrum, Potency, and Activity in Models of Acute InfectionClinical Infectious Diseases, 1986
- Pharmacokinetics of Sulbactam/Ampicillin in Humans: A ReviewClinical Infectious Diseases, 1986
- Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilliAntimicrobial Agents and Chemotherapy, 1986
- BETA-LACTAMASE ENZYMOGRAM - AGAR ADAPTATION OF THE IODOMETRIC METHOD1979